Physician profile

Suguna Pappu

Neurological Surgery · Maywood, IL

NPI 1134268121

$32,440.20

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$12.93

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Depuy Synthes Products, INC. $26,775.00 2021-2022
Medical Device Business Services, INC. $2,700.00 2021
Medtronic USA, INC. $1,804.81 2019
Abbott Laboratories $752.54 2019
Stryker Corporation $321.36 2019-2022
Orthofix Medical, INC. $73.56 2020
Medtronic, INC. $12.93 2023 Mazor X System

3 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Suguna Pappu

$32,440.20

in general payments reported 2019-2025

Years
2019-2023
Top company
Depuy Synthes Products, INC.

https://glasscript.com/doctor/709255/suguna-pappu

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.